Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > how do the few longs feel about jd leaving you?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Nov 05, 2022 2:46am
131 Views
Post# 35075405

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how do the few longs feel about jd leaving you?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how do the few longs feel about jd leaving you?Yo, Comonreally42, it's rather common in contracts for writers and other creatives to submit activity reports. It was a requirement in my contract that I do so. You can do your little girlie-giggle but it's an area that you don't know anything about because you couldn't write a grocery list. And you have your timing all wrong, Comon. I was under contract for a long time after DrDR took over. I kept this forum informed of ststus with Bioasis.

About Bioasis and NASDAQ, Bioasis discusses its plans for NASDAQ in both the latest MD&A and in the corporate presentation. If you don't know that, IQ42, then what specific interest do you have in Bioasis? Sue me on that one, see if you can get a free cup of coffee from a lawyer on it.

Gawd, MT, Comon talks about being a "sluth" and now you want to take the "bate." No one will ask you for an activity report.

I never mentioned illegal trading, MT. There was never any that I was aware of. I know there were promoters in the background that never revealed it. They posted on here for a long time. I always revealed my status with Bioasis. It's in the record, kids. About smoking guns, MT, go ahead and smoke anything you like. 

Fred Upchurch

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities